Topics

ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact

03:35 EST 14 Jan 2020 | Contract Pharma

To leverage CHO.RiGHT expression platform and DirectedLuck Transposase technology for generation of stable high-titer cell lines

Original Article: ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact

NEXT ARTICLE

More From BioPortfolio on "ProBioGen, Lava Therapeutics Sign Cell Line Mfg. Pact"

Quick Search